Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models

Trevor Hay1, Helen Jenkins, Owen J Sansom

  • 1School of Bioscience, Cardiff University, Cardiff, United Kingdom.

Cancer Research
|November 17, 2005
PubMed

Insights

PARP1 inhibition causes rapid cell death in Brca2-deficient cells, offering a potential new treatment strategy for BRCA2-related cancers and hereditary breast cancer.

Area of Science:

  • Genetics
  • Molecular Biology
  • Oncology

Background:

  • BRCA1 and BRCA2 genes are crucial tumor suppressors involved in DNA repair.
  • Mutations in BRCA2 are common in familial breast cancers and impair genomic stability.
  • Previous studies showed Brca2 deletion sensitizes mouse intestine to DNA damage.

Purpose of the Study:

  • To investigate the effect of poly(ADP-ribose) polymerase 1 (PARP1) inhibition on Brca2-deficient mouse small intestine.
  • To determine if PARP1 inhibition can induce cell death in normal Brca2-deficient cells.

Main Methods:

  • Conditional deletion of Brca2 in mouse small intestine.
  • Treatment of Brca2-deficient intestine with a PARP1 inhibitor.
  • Assessment of cell death (apoptosis) and tissue repopulation.

Main Results:

  • Brca2 deficiency made cells highly sensitive to PARP1 inhibition.
  • High levels of apoptosis were observed as early as 6 hours post-treatment.
  • Rapid tissue repopulation occurred in treated animals compared to controls.

Conclusions:

  • PARP1 inhibition demonstrates potent cell-killing effects in Brca2-deficient cells in vivo.
  • This strategy could be effective prophylactically for BRCA2 mutation carriers.
  • The findings suggest a potential therapeutic approach for BRCA2-deficient tumors.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
Base Excision Repair01:54

Base Excision Repair

One of the common DNA damages is the chemical alteration of single bases by alkylation, oxidation, or deamination. The altered bases cause mispairing and strand breakage during replication. This type of damage causes minimal change to the DNA double helix structure and can be repaired by the base excision repair (BER) pathways. BER corrects damaged DNA sequences by removing the damaged base and restoring the original base sequence using the complementary strand as a template.
The first step of...